Utilization of artificial intelligence for tumor segmentation in head and neck cancers: A systematic review and meta-analysis comparing PET with PET/CT imaging techniques - Takeaways - MDSpire

Utilization of artificial intelligence for tumor segmentation in head and neck cancers: A systematic review and meta-analysis comparing PET with PET/CT imaging techniques

  • By

  • Hamed Hajimokhtari

  • Tina Soleymanpourshamsi

  • Leila Rostamian

  • Ailar Yousefbeigi

  • Soheil Jafari

  • Asal Rezaeiyazdi

  • Mohammadjavad Askari

  • Maryam Khalilian

  • Parsa Vafaei

  • Mahla Esfahaniani

  • Gianrico Spagnuolo

  • Shirin Shahnaseri

  • Parisa Soltani

  • October 27, 2025

  • 0 min

Share

  • 1

    Head and neck cancers account for approximately 891,000 new cases and 458,000 deaths globally, highlighting the need for accurate diagnosis and treatment.

  • 2

    PET/CT imaging enhances tumor segmentation by combining metabolic and anatomical data, improving delineation before radiation therapy.

  • 3

    Deep learning-based auto-segmentation methods can reduce workload and improve accuracy in tumor boundary delineation for head and neck cancers.

  • 4

    PET-CT fusion has been shown to be more precise in tumor segmentation than single modalities, improving staging accuracy and treatment planning.

  • 5

    The HECKTOR challenge provided a benchmark for automatic segmentation of oropharyngeal tumors using PET/CT, advancing AI development in this field.

Original Source(s)

Utilization of artificial intelligence for tumor segmentation in head and neck cancers: A systematic review and meta-analysis comparing PET with PET/CT imaging techniques

  • by Hamed Hajimokhtari, Tina Soleymanpourshamsi, Leila Rostamian, Ailar Yousefbeigi, Soheil Jafari, Asal Rezaeiyazdi, Mohammadjavad Askari, Maryam Khalilian, Parsa Vafaei, Mahla Esfahaniani, Gianrico Spagnuolo, Shirin Shahnaseri, Parisa Soltani

  • October 27, 2025

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Case Report: [225Ac]Ac-PSMA-617 therapy in a patient with metastatic castration-resistant prostate cancer (mCRPC) and intracranial meningioma

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma